AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ferring Pharmaceuticals Secures Patient Access to EUFLEXXA ® with Blue Cross Blue Shield of Michigan

November 18, 2019 GMT

PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov 18, 2019--

Ferring Pharmaceuticals today announced that Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients will have access to EUFLEXXA, the #1 prescribed hyaluronic acid 1 (HA) for osteoarthritis knee pain, as a co-preferred brand beginning January 1, 2020. This solidifies EUFLEXXA as the #1 HA in patient access 2, offering simplified access with preferred status on many insurance plans.

Approximately 14 million Americans have symptomatic knee osteoarthritis, categorized as the degradation of cartilage in the knee. 3 Patients with knee osteoarthritis may experience pain, swelling and hindrances in joint movement. EUFLEXXA is a 3-course injection HA for patients with osteoarthritis knee pain.

“We are thrilled to announce that EUFLEXXA is a co-preferred option for eligible Blue Cross Blue Shield of Michigan members and physicians,” said Brent Ragans, Chief Commercial Officer, Ferring Pharmaceuticals. “Since 2005, Ferring has been committed to the orthopaedic space, and improving patient access to EUFLEXXA has remained a continued priority.”

Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients who are interested in learning more about this new offering should visit www.bcbsm.com to find out more details on their preferred products.

For more information about EUFLEXXA, or to find physicians in your area, please visit www.euflexxa.com.

EUFLEXXA Indication

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.

Important Safety Information

Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.

You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.

EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).

The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see here for full Prescribing Information for EUFLEXXA.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive medicine, maternal health, urology, gastroenterology, endocrinology, oncology, and orthopaedics. For more information, call 1-888-FERRING (1-888-337-7464); visit www.FerringUSA.com

____________________________
1 Rolling 12-month average of IQVIA claims data based on unique patients (August 2018-August 2019).
2 MMIT medical benefit data (October 2019); preferred status for commercial, Medicare Advantage, and managed Medicaid plans.
3 Athritis.org: Arthritis By The Numbers.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191118005192/en/

CONTACT: Heather Guzzi

Director, Brand Communications

Communications & Digital Innovation

1-862-286-5254

Heather.Guzzi@ferring.com

KEYWORD: MICHIGAN NEW JERSEY UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH MEDICAL SUPPLIES

SOURCE: Ferring Pharmaceuticals

Copyright Business Wire 2019.

PUB: 11/18/2019 08:00 AM/DISC: 11/18/2019 08:00 AM

http://www.businesswire.com/news/home/20191118005192/en